Penny Gilbert from Powell Gilbert LLP explains the position of biosimilars in the pharmaceutical industry. Biosimilars are essentially generic versions of biologics. Traditional generic compounds are  chemical reproductions of the patented compound which makes regulatory approval more straightforward. Biological compounds (proteins or antibodies which are produced from genes) are not identical with one another and…

Marleen H J van den Hors (BarentsKrans in the Netherlands) dealt with the interesting question of enforcement of second medical use patents and suggested that regulatory changes might be required to facilitate enforcement.  She pointed out that there has been different interpretations of Swiss-style claims in the Netherlands and the UK leading to a different…

A panel of international judges gave their interesting perspectives on the tribunals on which they serve and the cases which they hear. Annabelle Bennett (Federal Court of Australia) discussing case management in Australia introducing reforms to streamline procedure and how this has been successful (in taking some power away from the lawyers). In particular, she…

Dimitrios T Drivas (White & Case) gave the speedy run down on the following points and cases, which some might find useful for following up on points of interest: Supreme Court The decision that in exceptional cases reasonable attorney’s fees may be paid to the prevailing party (an exception to the rule that each party…